Related Experiment Video

Updated: Mar 11, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K

Beta blockers and mortality after myocardial infarction

    Nursing Older People
    |December 1, 2016
    PubMed

    Insights

    Beta blockers are beneficial for heart failure patients. However, older trials on their use after myocardial infarction did not include modern treatments like reperfusion therapy and statins.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Beta-blockers are established treatments for heart failure.
    • Previous clinical trials on beta-blockers post-myocardial infarction (MI) predate current therapeutic standards.

    Purpose of the Study:

    • To evaluate the efficacy of beta-blockers in acute myocardial infarction (MI) patients within the context of contemporary medical practice.
    • To assess the impact of beta-blockers considering advancements in reperfusion therapy and the availability of secondary prevention drugs like statins.

    Main Methods:

    • Review of existing clinical trial data.
    • Analysis of patient outcomes in trials conducted before and after the widespread adoption of reperfusion therapy and statins.

    Main Results:

    • Older trials may not accurately reflect the current benefit of beta-blockers in acute MI.
    • The efficacy of beta-blockers might be influenced by concomitant therapies and reperfusion strategies.

    Conclusions:

    • Re-evaluation of beta-blocker therapy in acute MI is warranted, considering modern treatment paradigms.
    • Current guidelines should account for the evolving landscape of cardiovascular pharmacotherapy and interventions.

    More Related Videos

    Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

    Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

    Published on: December 16, 2022

    4.6K
    A Modified Simple Method for Induction of Myocardial Infarction in Mice04:29

    A Modified Simple Method for Induction of Myocardial Infarction in Mice

    Published on: December 3, 2021

    4.7K

    Related Concept Videos

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
    1.8K
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    1.0K
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
    1.9K
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
    1.3K
    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
    1.6K
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
    2.2K